Apalutamide – July 2019

• Brand names:
  • Erlyand®
• Pharmaceutical Company:
  • Janssen-Cilag Pty Ltd
• Condition/Indication: Castration resistant prostate cancer
• Meeting Date: July 2019
• Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
• Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)

Related Public Summary Documents

• Apalutamide – November 2020
• Apalutamide – November 2021